Delamanid
- Generic Name
- Delamanid
- Brand Names
- Deltyba
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25F3N4O6
- CAS Number
- 681492-22-8
- Unique Ingredient Identifier
- 8OOT6M1PC7
- Background
Delamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall . It is used in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) in a combination regimen. Emergence of multidrug-resistant and extensively drug-resistant tub...
- Indication
Indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability .
- Associated Conditions
- Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
- Associated Therapies
- -
Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin
- Conditions
- Interventions
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Boston University
- Registration Number
- NCT02975570
Evaluating Newly Approved Drugs for Multidrug-resistant TB
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Médecins Sans Frontières, France
- Target Recruit Count
- 754
- Registration Number
- NCT02754765
- Locations
- 🇵🇪
Hospital Nacional Dos de Mayo Parque Historia de la Medicina, Lima, Peru
🇰🇿National Center for Tuberculosis Problems, Almaty, Kazakhstan
🇬🇪National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
Treatment Shortening of MDR-TB Using Existing and New Drugs
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 238
- Registration Number
- NCT02619994
- Locations
- 🇰🇷
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea, Republic of
Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2022-01-27
- Target Recruit Count
- 84
- Registration Number
- NCT02583048
- Locations
- 🇵🇪
Barranco CRS, Lima, Peru
🇿🇦Task Applied Science (TASK) CRS, Cape Town, Western Cape Province, South Africa
🇿🇦South African Tuberculosis Vaccine Initiative (SATVI) CRS, Cape Town, Western Cape Province, South Africa
A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 213
- Registration Number
- NCT02573350
- Locations
- 🇪🇪
Tartu University Lung Hospital, Tartu, Estonia
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Younsei University Medical Center, Seoul, Korea, Republic of
A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)
- Conditions
- Interventions
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2020-11-23
- Target Recruit Count
- 37
- Registration Number
- NCT01859923
- Locations
- 🇵🇭
Lung Center of the Philippines, Quezon City, Metro Manila, Philippines
🇵🇭De La Salle Health Sciences Institute, Dasmariñas, Cavite, Philippines
🇿🇦Brooklyn Chest Hospital, Ysterplaat, Cape Town, South Africa
Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2021-11-11
- Target Recruit Count
- 10
- Registration Number
- NCT01131351
- Locations
- 🇱🇹
Hospital for Tuberculosis and Lung Diseases, Siauliai, Lithuania
🇱🇻Infectology Center of Latvia - Clinic of Tuberculosis and Lung Diseases, Ogre, Latvia
🇱🇹National Tuberculosis and Infectious Diseases University Hospital, Vilnius, Lithuania
A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2021-12-01
- Target Recruit Count
- 481
- Registration Number
- NCT00685360
- Locations
- 🇵🇪
Hospital Nacional Sergio E. Bernales, Lima, Peru
🇵🇪Hospital Nacional Hipolito Unanue, Unanue, Peru
🇵🇪Hospital Nacional Daniel Alcides Carrión, Carrion, Peru
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Conditions
- Interventions
- Drug: darunavir/ritonavir dosage #1Drug: TAF w/cobicistatDrug: TAF w/cobicistat or ritonavirDrug: tenofovir alafenamide fumarate (TAF)Drug: elvitegravir/cobicistatDrug: darunavir/cobicistatDrug: atazanavir/cobicistatDrug: lopinavir/ritonavir dosage #1Drug: atazanavir/ritonavir/tenofovir dosage #1Drug: lopinavir/ritonavir dosage #2Drug: indinavir/ritonavir dosage #1Drug: fosamprenavir/ritonavirDrug: atazanavir/ritonavir dosage #1Drug: didanosine delayed release (Videx® EC)Drug: emtricitabineDrug: nelfinavir dosage #1Drug: tipranavir/ritonavirDrug: etravirineDrug: darunavir/ritonavir dosage #4Drug: indinavir/ritonavir dosage #2Drug: rilpivirineDrug: ethambutolDrug: efavirenzDrug: raltegravirDrug: dolutegravirDrug: kanamycinDrug: nevirapineDrug: amprenavirDrug: abacavirDrug: tenofovirDrug: maravirocDrug: darunavir/ritonavir dosage #2Drug: lopinavir/ritonavir dosage #3Drug: lopinavir/ritonavir dosage #4Drug: tenofovir/atazanavir/ritonavir dosage #2Drug: atazanavir/ritonavir dosage #2Drug: nelfinavir dosage #2Drug: rifampicinDrug: amikacinDrug: darunavir/ritonavir dosage #3Drug: etonogestrel implantDrug: capreomycinDrug: ethinyl estradiolDrug: isoniazidDrug: moxifloxacinDrug: levoflaxacinDrug: pyrazinamideDrug: ofloxacinDrug: ethionamide/prothionamideDrug: terizidone/cycloserineDrug: para-aminosalicylic acid (PAS)Drug: high dose INHDrug: bedaquilineDrug: clofazamineDrug: delamanidDrug: linezolidDrug: pretomanid
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 1578
- Registration Number
- NCT00042289
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.